Intranasal Oligonucleotide Delivery: Nanopharm & Aptar Pharma Data
Nanopharm and Aptar Pharma present new data at IPAC-RS NIF 2026 proving Antisense Oligonucleotide (ASO) biologics can be nasally delivered intact
The SmartTrack® validation study. Changing the game in regulatory approvals for generic OINDPs
Key takeaways from ISAM 2026: Nanopharm’s Lucas Silva on inhaled biologics, digital health and regulatory science in nasal and pulmonary drug delivery.
ISAM 2026: Looking Forward to the Next Chapter for Inhaled and Nasal Drug Delivery
Key takeaways from ISAM 2026: Nanopharm’s Lucas Silva on inhaled biologics, digital health and regulatory science in nasal and pulmonary drug delivery.